Lantheus Holdings Inc

Polaris Capital Management's Global Equity Strategy highlighted Lantheus Holdings in its second-quarter 2026 investor letter, citing strong quarterly earnings, the FDA approval of PYLARIFY TruVu, and intensified M&A interest from a potential $7 billion takeover bid by PE-backed Curium Pharma. The Polaris Global Equity Composite returned 13.26% net of fees for the quarter, trailing the MSCI World Index's 13.90% return with gross dividends reinvested, but remained ahead year-to-date through June 30, 2026, gaining 19.95% versus 9.94% for the benchmark. Lantheus closed at $100.28 per share on September 22, 2026, down 0.58% over the past month but up 92.62% over the past 52 weeks, with a market capitalization of $6.55 billion and a 52-week range of $49.67 to $111.86. Forty hedge fund portfolios held Lantheus at the end of the second quarter, up from 31 in the previous quarter.

Lantheus Holdings announced on Friday that the FDA has approved Tauklarify, a radiodiagnostic agent for detecting tau pathology in the brain of adults with Alzheimer’s disease using positron emission tomography. The approval covers use in cognitively impaired adults being evaluated for Alzheimer’s to determine whether tau neurofibrillary tangle pathology is present. The company said tau PET imaging complements amyloid PET and other diagnostic tools, and the approval is supported by data from two studies involving more than 500 patients who received a single intravenous dose. Lantheus CEO Mary Anne noted that clinicians are seeking a more complete understanding of the disease as the field advances.

Several major acquisition agreements were announced this week. DoubleVerify agreed to be acquired by Nielsen in an all-cash transaction valued at approximately $2.15 billion, with shareholders receiving $13.60 per share. Advanced Micro Devices signed a definitive agreement to acquire Taalas, a developer of specialized AI inference silicon. Visa agreed to acquire BioCatch, a provider of behavioral-first fraud intelligence, for $2.4 billion from funds advised by Permira. Prologis reached an agreement to buy SEGRO plc for about $18.8 billion after securing a board recommendation. Bending Spoons is acquiring Airtable in an all-cash transaction valuing the workflow software company at an enterprise value of $1.285 billion, implying an equity value of about $2.25 billion. Curium announced a deal to acquire all outstanding shares of Lantheus Holdings for up to $114.50 per share in cash, including contingent value rights. Atkore entered into a definitive agreement to be acquired by Prysmian in an all-cash transaction representing an enterprise value of approximately $3.8 billion. Supernus Pharmaceuticals and Indivior Pharmaceuticals agreed to merge in an all-stock merger of equals. Digital Brands Group shares surged after receiving a proposal from an existing shareholder to acquire all outstanding shares for $77.58 per share in cash. Gloo entered into a definitive agreement to acquire Cedarstone, a business services firm serving nonprofit organizations.

CapVest Partners-backed Curium has agreed to buy rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8 billion. Under the agreement, Curium US will purchase all outstanding shares of Lantheus for $102.50 per share upon closing, with shareholders also set to receive non-transferable contingent value rights that could provide up to an additional $12.00 per share if certain commercial milestones are met by 2030, bringing the potential total consideration per share to $114.50. The offer represents a 38% premium to Lantheus' 60-day volume-weighted average price and a 21% premium above its closing price as of 21 May 2026, the last day before media reports emerged about the potential sale. The proposed transaction has received unanimous approval from Lantheus' Board of Directors and is expected to close in the first half of 2027, subject to regulatory and shareholder approvals, with financing through a mix of debt and equity and no financial conditions attached.

Several major deals were reported this week across sectors. KKR is close to a deal to take medical-device outsourcer Integer Holdings private, sending its shares up 20%. Intercontinental Exchange agreed to acquire fixed-income electronic trading platform MarketAxess Holdings in a transaction valuing its equity at roughly $6.0 billion and total enterprise at $5.7 billion. Grant Thornton Advisors agreed to buy professional services firm CBIZ in an all-cash deal with a $5 billion enterprise value, backed by New Mountain Capital. Koch Inc. is exploring a sale of data center developer Edged that could value it at more than $15 billion. KKR and Energy Capital Partners agreed to acquire Ireland-based energy distributor DCC Energy in a deal valued at about £5.7 billion, with shareholders receiving £65.25 per share in cash plus a final dividend and a potential contingent payment. TransDigm Group agreed to acquire Prince & Izant from Industrial Growth Partners for approximately $1.066 billion in cash. argenx SE will acquire Forte Biosciences for $77 per share in cash, a transaction valued at roughly $2.2 billion, adding a first-in-class anti-CD122 antibody to its immunology portfolio. Ambarella shares surged 19% on a report that NXP Semiconductors is in talks to acquire the chip designer, though a deal is not certain. Curium is in advanced talks to buy radiopharma company Lantheus Holdings for about $102 per share upfront plus $12.50 per share in contingent value rights.

Bristol-Myers Squibb lifted its full-year outlook after reporting better-than-expected second-quarter 2026 results driven by higher sales of its cancer therapies. The company posted approximately $13.0 billion in revenue, beating consensus by $1.23 billion, with its growth portfolio contributing $7.6 billion. Adjusted earnings per share rose about 40% year-over-year to $2.04, exceeding estimates by $0.44. Bristol-Myers now expects full-year revenue of about $49.0 billion to $50.0 billion and adjusted EPS of $6.75 to $7.00, up from prior guidance and ahead of consensus. In other healthcare news, Johnson & Johnson agreed to pay up to $5.5 billion to settle remaining talc lawsuits alleging its products caused ovarian cancer, conditioned on at least 95% participation by claimants. Curium is in advanced talks to acquire Lantheus Holdings for about $7 billion upfront, with an additional $12.50 per share in contingent value rights, potentially valuing the deal at $8 billion. Boston Scientific shares slipped after its full-year outlook trailed consensus, despite second-quarter revenue of $5.4 billion beating estimates. Most Medicare Part D enrollees will face higher premiums in 2027 after the Trump administration ended a subsidy program, with three out of four seeing increases. The S&P 500 Health Care Index Sector edged up 0.12% during the week.